See more : Lotus Technology Inc. American Depositary Shares (LOT) Income Statement Analysis – Financial Results
Complete financial analysis of Zentalis Pharmaceuticals, Inc. (ZNTL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zentalis Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Onamba Co., Ltd. (ONMBF) Income Statement Analysis – Financial Results
- Intact Financial Corporation (INFFF) Income Statement Analysis – Financial Results
- Veeva Systems Inc. (VEE.DE) Income Statement Analysis – Financial Results
- Sonoro Energy Ltd. (SNV.V) Income Statement Analysis – Financial Results
- Webjet Limited (WEBJF) Income Statement Analysis – Financial Results
Zentalis Pharmaceuticals, Inc. (ZNTL)
About Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.00K |
| Cost of Revenue | 1.39M | 1.43M | 544.00K | 160.00K | 111.00K | 0.00 |
| Gross Profit | -1.39M | -1.43M | -544.00K | -160.00K | -111.00K | 14.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% |
| Research & Development | 189.59M | 172.73M | 175.60M | 84.90M | 38.39M | 18.92M |
| General & Administrative | 59.40M | 54.55M | 40.94M | 33.89M | 8.46M | 4.88M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 59.40M | 54.55M | 40.94M | 33.89M | 8.46M | 4.88M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -16.00K | 0.00 |
| Operating Expenses | 252.55M | 227.29M | 216.54M | 118.79M | 46.85M | 23.80M |
| Cost & Expenses | 253.94M | 227.29M | 216.54M | 118.79M | 46.85M | 23.80M |
| Interest Income | 0.00 | 2.26K | 1.31K | 1.24K | 498.00K | 355.00K |
| Interest Expense | 0.00 | 2.58M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.39M | 1.43M | 544.00K | 160.00K | 111.00K | 51.49K |
| EBITDA | -275.50M | -219.87M | -164.02M | -117.94M | -46.73M | -23.73M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -169,514.29% |
| Operating Income | -248.99M | -227.29M | -216.54M | -118.79M | -46.85M | -23.78M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -169,878.57% |
| Total Other Income/Expenses | -27.90M | 5.99M | 51.98M | 683.00K | 482.00K | 355.00K |
| Income Before Tax | -276.89M | -221.30M | -164.56M | -118.10M | -46.36M | -23.43M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -167,342.86% |
| Income Tax Expense | -601.00K | -469.00K | -297.00K | 444.00K | 15.00K | 4.00K |
| Net Income | -292.19M | -220.83M | -164.26M | -118.55M | -46.38M | -21.07M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -150,478.57% |
| EPS | -4.47 | -4.18 | -3.85 | -2.89 | -1.29 | -1.17 |
| EPS Diluted | -4.47 | -4.18 | -3.85 | -2.89 | -1.29 | -1.17 |
| Weighted Avg Shares Out | 65.41M | 52.86M | 42.69M | 41.04M | 35.88M | 18.06M |
| Weighted Avg Shares Out (Dil) | 65.41M | 52.86M | 42.69M | 41.04M | 35.88M | 18.06M |
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc
Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm
FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers
Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: https://incomestatements.info
Category: Stock Reports
What are Zentalis Pharmaceuticals’ Q2 2024 financial highlights?
Cash, Cash Equivalents and Marketable Securities Position: As of June 30, 2024, Zentalis had cash, cash equivalents and marketable securities of $426.4 million, which includes $27.8 million representing the June 30, 2024 fair value of Immunome common stock received by the Company as part of its upfront payment for the …